Stay updated with breaking news from Patrick Connor Johnson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
For adults with hematologic malignancies on CAR-T therapy, QoL declines and physical and psychological symptoms worsen 1-week postinfusion.
QOL deteriorates and physical and psychological symptoms worsen 1 week after infusion and then improve by 6 months postinfusion.
For patients with hematologic malignancies, 18, 22, and 22% have clinically significant depression, anxiety, PTSD at 6 months.
WEDNESDAY, April 5, 2023 (HealthDay News) -- A therapy that bolsters the immune system may not only help certain cancer patients live longer, but better, a new study finds.